H.C. Wainwright lowered the firm’s price target on Cabaletta Bio to $25 from $30 and keeps a Buy rating on the shares following the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio Unveils Updated Corporate Strategy Details
- Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
- Biotech Alert: Searches spiking for these stocks today